rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In addition, a double mutation resulting in V599K substitution was detected in two suspect ocular metastases of cutaneous melanoma.
|
14522889 |
2003 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Tumor-specific tandem mutations, encoding either V599K, V599R, or V599E, were found in 5 of 17 (29%) melanomas with BRAF exon 15 mutations.
|
15140228 |
2004 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Downstream of Ras, the serine/threonine kinase B-raf has been reported to be mutated, among other carcinomas, in a substantial subset of primary melanomas with a preponderance of mutations within the kinase domain including the activating V599E and V599K transitions.
|
15935100 |
2005 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.
|
16179870 |
2005 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We have evaluated five real-time ARMS assays: BRAF 1799T>A, [this includes V600E and V600K] and NRAS 182A>G [Q61R] and 181C>A [Q61K] in melanoma, EGFR 2573T>G [L858R], 2235-2249del15 [E746-A750del] in non-small-cell lung cancer, and compared the results to DNA sequencing of the mutation 'hot-spots' in these genes in formalin-fixed paraffin-embedded tumour (FF-PET) DNA.
|
20925915 |
2010 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Amongst BRAF-mutant melanoma, the frequency of non-V600E genotypes (including V600K) increased with increasing age.
|
22535154 |
2012 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Vemurafenib has been extensively tested on melanoma patients expressing the BRAFV600E mutated form; it has been demonstrated to be also effective in inhibiting melanomas carrying the V600K mutation.
|
22554099 |
2012 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Among the 20 melanomas with completed BRAF-sequencing analysis, 6 (30%) harbored a mutation, of which 5 (83%) had a V600E mutation and 1 (17%) had a V600R mutation.
|
22809251 |
2012 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
One (6·7%, 0·2-31·9) of 15 patients with Val600Lys BRAF-mutant melanoma achieved an overall intracranial response in cohort A, as did four (22·2%, 6·4-47·6) of 18 such patients in cohort B. Treatment-related adverse events of grade 3 or worse occurred in 38 (22%) patients.
|
23051966 |
2012 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We have treated 45 patients with V600 mutated melanoma including patients with V600R mutation between July 2011 and October 2012 with the selective BRAF inhibitor dabrafenib (n=43) or vemurafenib (n=2) via a compassionate access programme.
|
23237741 |
2013 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
V600R mutation and double (V600E -V600M) mutation were identified in two melanomas.In one case, V600K mutation was found.Two screening failures were noted.
|
23463675 |
2013 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In this study, sensitive and quantitative BRAF V600E and V600K mutation-specific real-time quantitative PCR was used to study the occurrence of small subsets of mutation-positive cells in primary melanomas and melanoma metastases.
|
23499336 |
2013 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
CAST-PCR gave rapid and accurate results for the common V600E and V600K mutations, however additional assays are required to detect rarer BRAF mutation types found in 3-4% of melanomas.
|
23584600 |
2013 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Melanomas had p.V600E (n = 30), p.V600K (n = 4), p.K601E (n = 1), p.600-601delinsE (n = 1), or no p.V600 mutations (n = 31).
|
23651150 |
2014 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
|
24508103 |
2014 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In a patient with a BRAF(V600K)-mutant melanoma responding to vemurafenib, we observed accelerated progression of a previously unrecognized NRAS-mutant leukemia.
|
24589925 |
2014 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
V600K, V600Q, and V600R BRAF melanomas did not positively stain with VE1.
|
24917033 |
2014 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The DDFI was significantly shorter in patients with BRAF(V600K/R) versus BRAF(V600E) melanoma in univariate and multivariate analyses.
|
24918823 |
2014 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Practical performance assessment employed 33 independent tissue samples, composed of 27 leukemias (by pyrosequencing: 8 wild-type; 18 mutated; 1 noninformative) and 6 melanomas (V600E; V600K; wild-type, 2 each).
|
25611237 |
2016 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?
|
26633701 |
2016 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In total, 88 patients (54%) had BRAFm melanoma (V600E/V600K).
|
26659191 |
2016 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
|
27219630 |
2016 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
These results support distinct etiologies for BRAF V600E, BRAF V600K, NRAS<sup>+</sup>, and wild-type melanomas.
|
28842324 |
2017 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
If confirmed using larger numbers of V600K tumors, our results may prove useful for designing clinical management and targeted chemotherapeutical interventions for BRAF V600K-positive melanomas.
|
28858076 |
2017 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The second patient had stage III BRAF V600R mutant melanoma that was treated with pembrolizumab and dabrafenib, and also developed a regressed melanocytic nevus.
|
29152725 |
2019 |